Peptide appearance Lyophilized form

Longevity and Anti-aging

15 000+ verified orders

MOTS-c

In stock

MOTS-c is a small peptide derived from mitochondrial genome. During metabolic stress, it moves to the nucleus to regulate the expression of nuclear genes, promoting cellular balance. It is co-expressed in various tissues with mitochondria, and found in plasma, though its levels decline with age. MOTS-c, discovered by researchers at the University of Southern California around 2012, improves glucose metabolism in skeletal muscle, suggesting benefits for diabetes, obesity, and aging. This peptide is being studied for its potential in treating cardiovascular disease, insulin resistance, and inflammation. Studies also explore molecular mechanisms and therapeutic potentials, suggesting synthetic biology as a new approach for developing and applying MOTS-c.
Available strengths
49,90 €
Buy 2, get 1 free. €100 in paid peptide vials · water excluded
Bundle & save

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

MOTS-c

Price range: 49,90 € through 148,50 €

Mitochondrial-derived peptide for cellular energy and stress-signalling studies.

Compound information

Specifications

Molecular profile

Sequence
Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
Molecular mass
2174.60 g/mol
CAS number
1627580-64-6
Molecular formula
C101H152N28O22S2

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
Mitochondrial-derived 16-amino-acid peptide; supplied strictly for research use only.

Research overview

MOTS-c

Description of MOTS-c

MOTS-c consists of 16 amino acids, and it belongs to the family of the mitochondrial-derived peptides, bioactive hormones, which are important for mitochondrial communication, and energy regulation. It has significant roles in glucose and lipid metabolic regulation, as well as in disease research. Research indicates that this peptide can influence insulin sensitivity, making it of interest in the context of type 2 diabetes research, and has been studied for its potential relevance to age-related decline and diseases, with investigations into longevity and healthspan by mitigating common metabolic dysfunctions associated with aging. Furthermore, it is being explored for its potential in research into obesity, cardiovascular diseases, and cancer. The discovery of MOTS-c highlights the influential role of mitochondrial peptides in cellular and systemic functions, opening new research avenues for metabolic and age-related diseases.

[1]

Overview of Published Research

MOTS-c is a novel peptide derived from mitochondrial DNA, which encodes 37 genes, including 22 tRNAs, 2 rRNAs, and 13 mRNAs. Mitochondria, ancient organelles with a semi-autonomous genetic system, still retain several bacterial-like qualities. MOTS-c, along with other mitochondrial-derived peptides (MDPs) like humanin, represents an expanded mitochondrial genetic repertoire with significant biological activities. These MDPs function as mitochondrial hormones, sending active signals at the cellular and organismal level. MOTS-c specifically targets skeletal muscle, influencing glucose metabolism and muscle uptake of glucose by increasing the expression of glucose transporters through AMPK activation. This activation is independent of the insulin pathway, offering an alternative means of influencing glucose uptake when insulin is ineffective or insufficient. Research findings indicate that MOTS-c influences muscle function, muscle protein deposition, and functional insulin resistance. It has implications for research into obesity, diabetes, exercise, and longevity, introducing a novel mitochondrial signaling mechanism for metabolic regulation within and between cells.

[2]

In studies involving mice, MOTS-c has demonstrated effects in research into metabolic dysfunction induced by ovariectomy (OVX), a procedure associated with increased adiposity and insulin resistance, common in postmenopausal women. MOTS-c treatment was observed to mitigate OVX-induced obesity and insulin resistance by influencing brown fat activation, reducing fat accumulation, and suppressing inflammatory responses in white adipose tissue. This intervention influenced energy dissipation and insulin sensitivity through AMPK pathway activation, underscoring MOTS-c's potential as a subject of research into menopause-induced metabolic dysfunction.

Moreover, recent research sheds light on MOTS-c's role beyond mitochondrial function, revealing its ability to translocate to the nucleus in response to metabolic stress. Once in the nucleus, MOTS-c regulates the expression of nuclear genes, particularly those involved in glucose restriction and antioxidant responses. This novel mechanism highlights the intricate communication between mitochondrial and nuclear genomes, suggesting a co-evolutionary process where factors encoded in both genomes cross-regulate each other to maintain cellular homeostasis. Additionally, MOTS-c's influence on fat metabolism is mediated through the activation of the AMPK pathway, a key regulator of cellular energy metabolism, offering potential insights into research applications in metabolic disorders and aging-related conditions.

Furthermore, MOTS-c exhibits exercise-mimetic properties and influences insulin sensitivity in aged and diet-induced obese mice. Through an unbiased metabolomics approach, it was found that MOTS-c administration reduced sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways, which are typically upregulated in obese and type 2 diabetes (T2D) models. This effect of MOTS-c is associated with improved insulin sensitivity, increased beta-oxidation, and prevention of fat accumulation, particularly in the context of obesity. Dysregulation of fat metabolism in mitochondria, possibly due to mitochondrial dysfunction, leads to a lack of fat oxidation, resulting in increased circulating fat levels and insulin resistance.

Research suggests a link between hepatic mitochondrial dysfunction and diet-induced insulin resistance, as mitochondria play a crucial role in ATP production and lipid oxidation. Dysfunctional mitochondria may contribute to ectopic fat accumulation in the liver, leading to insulin resistance and the development of metabolic disorders such as obesity, type 2 diabetes mellitus, and non-alcoholic steatohepatitis. Studies show impaired hepatic mitochondrial function in obesity and insulin resistance models induced by high-fat or high-fructose diets. Understanding the role of mitochondrial dysfunction in fat metabolism and insulin resistance sheds light on the mechanisms underlying metabolic disorders and offers potential research targets. MOTS-c's observed capacity to influence fat metabolism and insulin sensitivity highlights its significance in the context of metabolic dysfunction research and offers novel insights into further investigation of obesity and diabetes.

[3] - [6]

Plasma MOTS-c levels are associated with insulin sensitivity, particularly in lean individuals, but not in obese individuals. Although MOTS-c concentration remains similar between lean and obese individuals, it correlates positively with insulin resistance surrogates, such as the HOMA index and Matsuda index, only in lean subjects. This suggests that plasma MOTS-c concentration depends on metabolic status, with its association with insulin sensitivity altered in the presence of obesity. These findings highlight the potential of plasma MOTS-c as a biomarker for monitoring insulin sensitivity, particularly in pre-diabetic lean individuals, where changes in MOTS-c levels could serve as an early indicator of insulin resistance. Research into MOTS-c may offer insights into preventive strategies against insulin resistance and the development of diabetes. However, further research is needed to fully understand the role of MOTS-c in insulin regulation and its impact on metabolic homeostasis in humans.

[7]

MOTS-c has been studied in the context of osteoporosis, with findings suggesting it may influence the synthesis of type I collagen in osteoblasts through the TGF-β/SMAD signaling pathway. In experiments with hFOB1.19 cells, MOTS-c treatment increased cell viability in a time-dependent manner and upregulated mRNA and protein expressions of TGF-β, SMAD7, COL1A1, and COL1A2. The concentration of MOTS-c influenced the expressions of these genes, and knockdown of TGF-β or SMAD7 partially reversed the increase in collagen expression, indicating the involvement of the TGF-β/SMAD pathway. Thus, MOTS-c appears to promote osteoblasts to synthesize type I collagen via this pathway.

Furthermore, MOTS-c is implicated in influencing osteogenesis by stimulating the differentiation of bone marrow stem cells through the TGF-β/SMAD pathway. This is associated with increased formation of new bone, highlighting MOTS-c's role in both influencing osteoblasts and their development from stem cells. These findings suggest that MOTS-c may play a role in bone health and integrity, making it a potential subject of research in the context of osteoporosis.

[8], [9]

MOTS-c peptide has emerged as a potential factor of research interest in exceptional longevity, particularly in certain human populations such as the Japanese. Research suggests that a specific change in the MOTS-c gene, found exclusively in individuals with Northeast Asian ancestry, may be associated with this longevity. This change involves the substitution of a glutamate residue for the lysine normally found in position 14 of the protein, though the functional implications of this alteration are not yet fully understood. However, it is believed to affect both the structure and function of MOTS-c, potentially influencing its role in longevity research.

Dr. Changhan David Lee, a researcher at USC Leonard Davis School of Gerontology, highlights the importance of mitochondrial biology in research into extending lifespan and healthspan in humans. Mitochondria, as the primary metabolic organelle, are strongly implicated in aging and age-related diseases. While dietary restriction has been the main method for impacting mitochondrial function and longevity, peptides like MOTS-c offer a promising avenue for directly investigating mitochondrial function. This suggests that MOTS-c and similar peptides could have significant implications for research into extending lifespan and improving health in humans by targeting mitochondrial function.

[10]

The study investigated the association between circulating MOTS-c levels and endothelial dysfunction (ED) in patients without significant structural coronary lesions. Forty patients undergoing coronary angiography and endothelial function testing were included, divided into normal endothelial function and ED groups based on coronary blood flow response to acetylcholine. Aortic plasma samples revealed lower MOTS-c levels in patients with ED compared to those with normal endothelial function. Plasma MOTS-c levels correlated positively with microvascular and epicardial coronary endothelial function. While MOTS-c did not directly impact blood vessel responsiveness, pretreatment with MOTS-c influenced vessel responsiveness to acetylcholine in rodent models. These findings suggest that lower circulating MOTS-c levels are associated with impaired coronary endothelial function, indicating MOTS-c as a potential research subject in the context of ED.

Mitochondria-derived peptides (MDPs) like MOTS-c play crucial roles in regulating cellular metabolism and maintaining mitochondrial function and cell viability. Recent research highlights the relevance of MDPs to cardiovascular disease (CVD) research, with MOTS-c showing promise as a research subject. Studies demonstrate that lower MOTS-c levels correlate with higher endothelial cell dysfunction, a key factor in CVD development. Additionally, MOTS-c influences endothelial cell responses to signaling molecules like acetylcholine, affecting endothelial function. MDP dysregulation is implicated in various aspects of CVD, suggesting their potential as biomarkers or research targets.

[11], [12]

All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Analytical documentation

Tests

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

99.2%Purity by HPLC

Batch number
2026239
Tested
2026-05-28

Recorded QC panel

AssayPeptide screening
10.39 mg
PurityPeptide screening
99.2%
Identity (FTIR)FTIR spectrum
997
Identity (RT)Retention time
0.989

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Signed certificate

Source record

References

1.

Y. Zheng et al., "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation", 2023.

2.

C. Lee, K. H. Kim, and P. Cohen, "MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism," Free Radic. Biol. Med., vol. 100, pp. 182–187, Nov. 2016. [PMC]

3.

H. Lu et al., "MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction," J. Mol. Med. Berl. Ger., vol. 97, no. 4, pp. 473–485, Apr. 2019. [PubMed]

4.

K. H. Kim, J. M. Son, B. A. Benayoun, and C. Lee, "The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress," Cell Metab., vol. 28, no. 3, pp. 516-524.e7, Sep. 2018. [PMC]

5.

S.-J. Kim et al., "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity," Physiol. Rep., vol. 7, no. 13, p. e14171, Jul. 2019. [PubMed]

6.

R. Crescenzo, F. Bianco, A. Mazzoli, A. Giacco, G. Liverini, and S. Iossa, "A possible link between hepatic mitochondrial dysfunction and diet-induced insulin resistance," Eur. J. Nutr., vol. 55, no. 1, pp. 1–6, Feb. 2016. [BMJ]

7.

L. R. Cataldo, R. Fernández-Verdejo, J. L. Santos, and J. E. Galgani, "Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals," J. Investig. Med., vol. 66, no. 6, pp. 1019–1022, Aug. 2018. [PubMed]

8.

N. Che et al., "MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway," Eur. Rev. Med. Pharmacol. Sci., vol. 23, no. 8, pp. 3183–3189, Apr. 2019. [PubMed]

9.

B.-T. Hu and W.-Z. Chen, "MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway," Eur. Rev. Med. Pharmacol. Sci., vol. 22, no. 21, pp. 7156–7163, Nov. 2018. [PubMed]

10.

N. Fuku et al., "The mitochondrial-derived peptide MOTS-c: A player in exceptional longevity?," Aging Cell, vol. 14, Aug. 2015. [Research Gate]

11.

Q. Qin et al., "Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction," Int. J. Cardiol., vol. 254, pp. 23–27, 01 2018. [PubMed]

12.

Y. Yang et al., "The role of mitochondria-derived peptides in cardiovascular disease: Recent updates," Biomed. Pharmacother. Biomedecine Pharmacother., vol. 117, p. 109075, Jun. 2019. [PubMed]

13.

National Center for Biotechnology Information

PubChem Compound Summary: MOTS-c

Authoritative identity record for the mitochondrial-derived peptide MOTS-c.

PubChem View source ↗
14.

Lee C, Zeng J, Drew BG, et al. · 2015

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Primary report identifying MOTS-c as a mitochondrial-derived peptide.

Cell Metabolism · 10.1016/j.cmet.2015.02.009 View source ↗
15.

Chemical Abstracts Service

CAS Common Chemistry: 1627580-64-6

Authoritative CAS Registry Number record for MOTS-c.

CAS Common Chemistry View source ↗
16.

National Center for Biotechnology Information

NCBI Gene: MT-RNR1 mitochondrial 12S rRNA

Authoritative gene record for the mitochondrial transcript that encodes MOTS-c.

NCBI Gene View source ↗
17.

Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Hirose N · 2015

The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?

Aging cell View source ↗
18.

Kim SJ, Miller B, Mehta HH, Xiao J, Wan J, Arpawong TE, Yen K, Cohen P · 2019

The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity

Physiological reports View source ↗
19.

Y. Zheng et al. · 2023

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

2023
20.

C. Lee, K. H. Kim, and P. Cohen · 2016

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

Free Radic. Biol. Med
21.

H. Lu et al. · 2019

MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction

J. Mol. Med. Berl. Ger
22.

K. H. Kim, J. M. Son, B. A. Benayoun, and C. Lee · 2018

The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress

Cell Metab
23.

R. Crescenzo, F. Bianco, A. Mazzoli, A. Giacco, G. Liverini, and S. Iossa · 2016

A possible link between hepatic mitochondrial dysfunction and diet-induced insulin resistance

Eur. J. Nutr
24.

L. R. Cataldo, R. Fernández-Verdejo, J. L. Santos, and J. E. Galgani · 2018

Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals

J. Investig. Med
25.

N. Che et al. · 2019

MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway

Eur. Rev. Med. Pharmacol. Sci
26.

B.-T. Hu and W.-Z. Chen · 2018

MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway

Eur. Rev. Med. Pharmacol. Sci
27.

Q. Qin et al. · 2018

Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction

Int. J. Cardiol
28.

Y. Yang et al. · 2019

The role of mitochondria-derived peptides in cardiovascular disease: Recent updates

Biomed. Pharmacother. Biomedecine Pharmacother

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →